

U.S. Food and Drug Administration Division of Pharmaceutical Quality Operations III 300 River Place, Suite 5900 Detroit, MI 48207

Telephone: (313) 393-8100 Fax: (313) 393-8139

www.fda.gov

April 3, 2019

UPS NEXT DAY SIGNATURE REQUIRED

Ambreen Jafri WellRx LLC dba HomeRx LLC 200 E Willow Ave, Suite 100 Wheaton, IL 60187

Dear Ms. Jafri:

We are enclosing a copy of the Establishment Inspection Report (EIR) for the inspection conducted at your facility, WellRx LLC dba HomeRx LLC, located at 200 E Willow Ave, Suite 100, Wheaton, IL 60187, from October 2, 2017, to November 13, 2017, by the U.S. Food and Drug Administration (FDA). In addition, we are enclosing the letter sent to the Illinois State Board of Pharmacy for follow up.

When the Agency considers an inspection to be "closed" under 21 C.F.R. 20.64(d)(3), it will release a copy of the EIR to the inspected establishment.

The Agency continually works to make its regulatory process and activities more transparent for regulated industry. Releasing this EIR to you is part of this effort. The copy being provided to you comprises the narrative portion of the report; it may reflect redactions made by the Agency in accordance with the Freedom of Information Act (FOIA) and 21 C.F.R. Part 20. This, however, does not preclude you from requesting and possibly obtaining any additional information under FOIA.

If there is any question about the released information, please contact Russell Riley, Compliance Officer, at (630) 323-2763 ext. 101, or by email at: ORAPHARM3 RESPONSES@fda.hhs.gov.

Sincerely,

Nicholas F. Lyons -S Digitally signed by Nicholas F. Lyons -S DN: c=US, o=US. Government, ou=HHS, ou=FDA, ou=People, 0.9.2342.19200300.100.1.1=1300120033, cn=Nicholas F. Lyons -S Date: 2019.04.03 11:07:00 -05'00'

Nicholas F. Lyons Compliance Director

Division of Pharmaceutical Quality Operations III

Enclosure: EIR and State Referral Letter